PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carolyn Sasse of Astellas highlights the company’s ophthalmology pipeline.
Sasse provides updates about post-marketing safety data for Izervay (avacincaptad pegol intravitreal solution) and a phase 1 trial that is currently recruiting patients with geographic atrophy secondary to age-related macular degeneration.
“Over the past decade, we have established a leading early-stage ophthalmology pipeline that includes cell and gene therapies to treat diseases such as geographic atrophy and